Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
This analysis points to fund families that consistently stood out in index fund history, helping you recognize dominant players over time.
25,021 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
CrowdStrike has become a pillar in AI-era cybersecurity, but a 14% decline raises the question: is it a buy? This gui...
A reported breakthrough on Iran negotiations sparked a risk-on market rally and shifted bets on the Federal Reserve's...
Oil prices tumbled to their lowest levels since early March as a tentative Iran agreement raised hopes of easing tank...
Strategy’s flagship STRC yield product slid to yearly lows as Bitcoin volatility intensified, weighing on the company...
A Parabilis Medicines director recently disclosed a substantial stake just after the company’s fresh IPO. This articl...
Investing in homebuilders can be fast-moving. This article explains why a home stock jumped today, the catalysts behi...
What happens when AI breakthroughs and high-flying tech bets collide with political markets? This article explains th...
Netflix trades near its 52-week low as operating strength clashes with subscriber-growth concerns. A stronger FY26 ca...
Investing in biotech can be bold. This piece lays out practical scenarios for what much could $1,000 invested in Viki...
Occidental Petroleum climbs on an Evercore upgrade and a stronger oil backdrop, outpacing ExxonMobil and Chevron as t...
Figma posted impressive numbers in early 2026, yet the stock slumped. This article breaks down the drivers behind fig...